Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Current progress in SARS-CoV-2 vaccine candidates

In a new study, researchers illustrated the current progress and obstacles in COVID-19 vaccine development.

7 Mar 2022

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Researchers estimated the immunogenicity of SARS-CoV-2 vaccination in a Belgian cohort of patients with ankylosing spondylitis.

7 Mar 2022

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

A new study assesses breakthrough SARS-CoV-2 infections in vaccinated CLD patients with cirrhosis as compared to CLD patients without cirrhosis.

3 Mar 2022

Additional doses of covid-19 vaccine recommended for immunocompromised patients

Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, say experts in The BMJ today.

3 Mar 2022

Study compares heterologous and homologous third vaccination in kidney transplant recipients

A new study assesses the comparative neutralizing antibody level elicited by three mRNA vaccine doses to a heterologous COVID-19 vaccine regimen.

28 Feb 2022

Breakthrough SARS-CoV-2 infection peaks at 5 months

A new study describes the incidence of breakthrough infection with SARS-CoV-2 after vaccination with one of the nucleic acid or viral vector vaccines.

28 Feb 2022

Emergence of SARS-CoV-2 Omicron likely due to immune selective pressure

A new study discusses the emergence of new variants of SARS-CoV-2 that can escape antibody-mediated neutralization, as opposed to other Sarbecoviruses.

27 Feb 2022

A comparison of COVID-19 vaccines by neutralizing antibody potency

Researchers use an international standardized assessment method to compare the efficacy of antibody responses to the major COVID-19 vaccines.

24 Feb 2022

Gradual decline in pathogenicity and enhanced cytokine induction in SARS-CoV-2 variants

A new study focuses on understanding the factors associated with the ability of the Omicron variant to infect a wide range of age groups.

20 Feb 2022

TTUHSC project awarded new NIH grant to advance research on amygdala pain mechanisms

It is estimated that more than 100 million U.S. adults are affected by chronic pain, a condition that annually costs the country an estimated $560-635 billion in health care costs, disability and lost productivity.

1 Feb 2022

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

In the recently published study in The Lancet, first-authored by Dr. Sue Ann Costa Clemens from the University of Oxford in the United Kingdom and the University of Siena in Italy, a comprehensive analysis has been pursued on the immunogenicity and safety of both homologous and heterologous boosting after receiving the inactivated vaccine CoronaVac.

26 Jan 2022

Heterologous vaccine schedule provides extraordinary response to third dose of coronavirus vaccines

A third, booster dose of either the ChAdOx1 nCoV-19 (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), AD26.COV2-S (Janssen) or CoronaVac (SinoVac) coronavirus vaccine induce a significant increase in antibody levels in those who have previously received two doses of CoronaVac.

25 Jan 2022

Humoral correlate of protection for SARS-CoV-2 may reduce COVID-19 infection risk

In a new study, a team of researchers reviewed the published literature to find evidence for humoral SARS-CoV-2 correlate of protection (CoP).

25 Jan 2022

Even mild SARS-CoV-2 respiratory-only infection can cause long-term neurologic damage

A new bioRxiv* preprint study led by Michelle Monje of Stanford University in California finds that a mild COVID-19 infection can produce long-term neurological damage. Persistent cognitive complications are one of many symptoms of long COVID, and the latest results suggest the severity of COVID-19 induced brain fog is similar to cancer’s “chemobrain.”

16 Jan 2022

Insignificant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens

Researchers determine whether sequences within SARS-CoV-2 could lead to an immune response to autoantigens associated with autoimmune myocarditis.

13 Jan 2022

Virus-like particles as delivery vehicles for gene-editing

Scientists deliver gene-editing proteins through the use of engineered virus-like particles, which mediated efficient base editing both in vitro and in vivo.

13 Jan 2022

Distrust in state power closely linked vaccine hesitancy

Distrust of the state in Turkey, religion and abortion resistance in the United States. Politics and culture are just as important in explaining vaccine hesitancy as health.

5 Jan 2022

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

Reviewing myocarditis and pericarditis in immunosuppressed individuals following COVID-19 mRNA vaccination

A new study did not conclusively correlate the incidence of myocarditis or pericarditis with mRNA vaccination against SARS-CoV-2.

30 Dec 2021

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

One dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptomatic COVID-19 and 91.7% effective against severe COVID-19 disease beginning 28 days postvaccination, according to a phase 3 randomized controlled trial published in The Lancet.

23 Dec 2021